Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
